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Abstract
The actual task of oncology is effective treatment of cancer while causing a minimum harm to the patient. The
appearance of polymer nanomaterials and technologies launched new applications and approaches of delivery and
release of anticancer drugs. The goal of work was to test ultra dispersed diamonds (UDDs) and onion-like carbon
(OLCs) as new vehicles for delivery of antitumor drug (doxorubicin (DOX)) and specific antibodies to tumor
receptors. Stable compounds of UDDs and OLCs with DOX were obtained. As results of work, an effectiveness of
functionalization was 2.94 % w/w for OLC-DOX and 2.98 % w/w for UDD-DOX. Also, there was demonstrated that
UDD-DOX and OLC-DOX constructs had dose-dependent cytotoxic effect on tumor cells in the presence of trypsin.
The survival of adenocarcinoma cells reduced from 52 to 28 % in case of incubation with the UDD-DOX in
concentrations from 8.4–2.5 to 670–20 μg/ml and from 72 to 30 % after incubation with OLC-DOX. Simultaneously,
antibodies to epidermal growth factor maintained 75 % of the functional activity and specificity after matrix-assisted
pulsed laser evaporation deposition. Thus, the conclusion has been made about the prospects of selected new
methods and approaches for creating an antitumor agent with capabilities targeted delivery of drugs.
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Background
Nanotechnology enables to carry out controlled manipu-
lation with substances at the level of 1 nm. That actually
means to control physical, chemical, and biological pro-
cesses at atomic and molecular scale [1–6]. Methods
and vehicles are created for targeted transportation of
drugs and biologically active substances in the body and
active diagnostic devices for express analysis. It can be
used for biotechnology, pharmaceuticals, and medicine
purpose [7–13]. One of the focuses of the anticancer in-
vestigations is a search for effective antitumor drugs by
inhibition of tumor cell proliferation, metabolism, and
metastatic activity [14, 15]. Doxorubicin is one of such
inhibitors [16–19]. Doxorubicin is an anthracycline drug
which was extracted from Streptomyces peucetius var.
caesius in the 1970s. There are two proposed mechanisms
by which doxorubicin acts in the cancer cell: (i) intercal-
ation into DNA and disruption of topoisomerase-II-
mediated DNA repair and (ii) generation of free radicals
and their damage to cellular membranes, DNA, and pro-
teins. In brief, doxorubicin is oxidized to semi-quinone, an
unstable metabolite, which is converted back to doxorubi-
cin in a process that releases reactive oxygen species. Re-
active oxygen species can lead to lipid peroxidation and
membrane damage, DNA damage, and oxidative stress
and triggers apoptotic pathways of cell death [20]. Accord-
ing to the classification of chemotherapeutic agents by
mechanisms of action, doxorubicin is referred to antime-
tabolites as far as it can intercalate with DNA and cyto-
toxic antibiotics of anthracycline family because it affects
topoisomerase II enzyme [21]. As a result, doxorubicin
significantly reduced the proliferation and survival of
tumor cells. However, the cytotoxic activity of doxorubicin
has no specificity, which leads to serious side effects of the
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gastrointestinal tract, liver, and kidneys. It is noteworthy
that such side effects inherent to the action of many anti-
cancer drugs. We maintain opinion that solution is in
usage of specific polymer materials which combine func-
tion of drugs vehicle and holder of antibodies to specific
receptors of tumor cells. The possibility for receptor-
dependent influence on tumor cells and targeted delivery
of antitumor agent to cells with specific receptor profile is
very attractive and promising area of anticancer research
[22–25]. Based on earlier studies, there was proposed the
hypothesis of creating carbon-protein constructs for tar-
geted delivery of drugs, growth factors, and biologically
active substances on the base of carbon nanomaterials
(CNMs). As a biologically inert basis for accession drug
and tumor-specific antibodies, we propose ultra dis-
persed diamonds (UDDs) and onion-like carbons (OLCs)
[1, 3, 10]. Thus, the goal of our work was to syntheses an-
titumor nanocarbon-protein conjugates (NCPCs) on the
basis of carbon “nucleus” (UDDs or OLCs) with specific
antibodies to the tumor-specific receptor of epidermal
growth factor (EGFR) and antimetabolic anthracycline
drug (doxorubicin (DOX)). The novelty of investigation
idea is in combination of anti-proliferation properties of
DOX and receptor—specific binding of antibodies to
EGFR for targeted increasing concentration of DOX in tis-
sue niches which over-expressed of EGFR. In such way, ef-
fectiveness of the antitumor treatment will be increased
and level of hum full side effect will be minimized. As a
biologically inert vehicle for accession DOX and anti-
EGFR antibodies, we propose to use UDD or OLC aggre-
gates. Then, methods of controlled releasing of DOX were
tested. Due to estimated cellular responses on different
concentrations of CNMs, DOX, NCPCs, MCF-7, and
HT29 cells, viability was measured. Afterwards, activity of
antibodies to EGFR after matrix-associated pulse laser
evaporated (MAPLE) deposition on carbon surface was
analyzed. In the results obtained, NCPCs allowed to
realize sustained release of DOX and demonstrated excel-
lent dose-dependent cytotoxicity to tumor cells and bio-
compatibility in inactivated form. So, these NCPCs with
DOX represent a platform for targeted delivery and for
cell-specific release of antitumor drugs.
Methods
Cell Lines
Breast adenocarcinoma cell line MCF-7 and hepatocellu-
lar carcinoma HT29 was kindly presented by the bank of
cell lines of man and animals R.E.Kavetskiy’ Institute of
Experimental Pathology, Oncology and Radiobiology of
NAS of Ukraine. Cells were incubated under standard
conditions in 5 % of CO2 and 100 % humidity in RPMI-
1640 medium (Sigma, USA). Full medium was supple-
mented with 10 % fetal bovine serum (FBS, Sigma, USA)
and 40 mg/ml gentamycin (Sigma) for cell culture.
Serum-free medium was not supplemented with FBS.
Cells were cultured in sterile 96-well plates, 6-well plates,
25-cm2 flasks (Nunc, Denmark).
Purification of the CNMs
Purification of UDDs and OLCs from the metal/catalyst
was performed by HF treatment. Elimination of amorph-
ous carbon from carbon nanomaterials was realized by
oxidation in air at 450–500 °C. This purification method
is very simple: the crude sample containing UDD and
OLC reacted with oxygen (from air) and created carbon
dioxide or carbon monoxide. Some amount of carbon
deposit has been obtained after HF (aqua) dissolution of
the catalyst support were oxidized in air at 450–500 °C.
An air flow quartz tubular reactor was used for this pro-
cedure for 130–150 min. We analyzed and described
physical and chemical characteristics of obtained UDD
and OLC in previous work [26].
Oxidation of UDDs and OLCs
On the next step, the purified carbon nanomaterials
(CNMs) were oxidized in 70 % HNO3 at 99 °C for 4 h and
then washed with distilled water and 10 % NH4OH solution
for 12 h. As a result, carbon nanomaterial oxides: ultra dis-
persed diamond oxides (UDDox) and onion-like carbon ox-
ides (OLCox), were synthesized. After that CNMs were
washed thrice with dH2O to neutral pH. The acidic sites on
CNM surface were regenerated with 0.1 M HCl solution.
The resulting oxidized CNMs-ox were separated by centri-
fugation, rinsed extensively, and re-suspended in DI water.
Preparation of CNM-DOX Particles
The task of the next step was to immobilize DOX hydro-
chloride (DOX, Teva Nederland B.V, Netherlands) on the
surface of UDDox or OLCox particles (UDD-DOX or
OLC-DOX). To functionalize the surfaces of oxidized
CNMs and UDDox/OLCox (200 mg) by amino containing
DOX-lactose monohydrate, they were incubated with bi-
functional linking agent—N-cyclohexyl-N′-(2-morpholi-
noethyl) carbodiimide metho-p-toluenesulfonate (C 1011,
Sigma Aldrich, USA) during 15 min at room temperature
(Fig. 1). After that, 58 mg DOX-lactose monohydrate was
added into 10 ml of 0.15 M phosphate buffer pH 6.5 to
each nanocarbon materials. The mixture was allowed to
react at 30 °C for 24 h. In such conditions, covalent binds
between DOX and CNMs were formed (Fig. 2). The com-
position were collected by centrifugation at 10,000 rpm
15 min and washed with dH2O thrice. Supernatants were
used for detection concentration of free DOX by
spectrophotometer.
FT-IR Spectroscopy of UDD-DOX Particles
The chemical composition of the obtained composition
was investigated by FT-IR spectroscopy. IR spectra were
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determined by FTS 7000e Varian FTIR spectrometer.
Samples for analysis were prepared by grinding in a mill
of a mixture of ~1 mg of nanomaterials and 150 mg of
spectrally pure KBr. Samples were prepared by using a
press with a pressure force of 3.0–3.5 × 103 kg/cm2. Pre-
shot spectra of KBr were preliminary obtained, and then,
they are subtracted from the spectra of the samples. All
spectra of UDD, DOX, and UDD-DOX were recorded
by the same technology. All conditions of handling, sam-
ple preparation, and compositions were similar for the
all substances.
Colorimetric Assay
To monitor the amount of free DOX after immobilization
on CNMs and the effectiveness of the DOX release, the
ability of free DOX to fluorescent at a wavelength of
495 nm was used [27]. Active concentration of DOX was
16.7 % w/w from 3.34 mg/ml to 16.3 μg/ml. For the
purpose of drawing the calibration lines, DOX Teva
20 mg/ml with ten dilutions to 8 × 10−3 mg/ml was used.
Then, the fluorescence of free DOX was measured in
supernatant from complexes DOX with UDD and OLC by
spectrophotometric plate reader Multyscan (Labsystem,
Finland).
DOX Concentration in UDD-DOX and OLC-DOX Particles
For DOX immobilizations, 25 mg of UDDox or OLCox
was used. The amount of DOX-TEVA was 2.25 mg of
(0.75 mg of active DOX) in 1 ml dH2O. The amount
of free DOX in supernatant after reaction was
14.3 μg or 1.9 % for OLC-DOX and 10.2 μg or 1.4 %
for UDD-DOX. Thus, we made the conclusion that
735.7 μg of DOX was immobilized on 25 mg of
OLCox and 739.8 μg of DOX was immobilized on
25 mg of UDDox in 1 ml dH2O. Effectiveness of
functionalization was 2.94 % w/w for OLC-DOX and
2.98 % w/w for UDD-DOX. Further calculation of
concentrations UDD-DOX and OLC-DOX are based
on these data.
MAPLE Deposition of Antibodies to EGFR
MAPLE (Fig. 3) is a deposition technique [28] de-
rived from pulsed laser deposition (PLD) in order to
avoid laser radiation-induced damage to biologic or
organic molecules or compounds. Such a result is
achieved carrying out laser deposition from a frozen
target containing the guest material to be deposited
in a volatile matrix [29–32]. As specific MAPLE
characteristic, the presence of the matrix protects
guest material from being damaged by laser radiation
but deposition is essentially solvent-free since matrix
molecules do not reach substrate. This allows multi-
layer depositions using the same solvent and deposi-
tions on soluble substrates. The steps for production
of antibody-CNM-DOX nanoparticles were as
follows:
Fig. 1 A scheme shows the mechanism of carboxyl group activation with carbodiimide. The reaction proceeded at room temperature during 15 min
Fig. 2 A scheme shows the mechanism of binding doxorubicin to UDD or OLC surface by protein covalent links. Reagents interacted at 30 °C for 24 h
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(a)A soluble layer was created on a MAPLE substrate
(a microscope cover glass) by placing it at the
bottom of a 5-mm deep container filled with sterile
saline solution (9 mg/ml NaCl in water from
Fresenius Kabi) and letting water to evaporate at
95 °C and atmospheric pressure for about 12 h.
(b)A layer containing the required nanoparticles
(OLC-DOX or UDD-DOX, see Table 1 for details)
was deposited on the top of the soluble layer by
taking advantage of the solvent-free behavior of
MAPLE technique. The MAPLE target was obtained
by dispersing nanoparticles in aqueous or saline
solution. The target was frozen by placing it in
thermal contact with liquid nitrogen. The vacuum
chamber pressure was then lowered and laser turned
on. Laser beam impinges at an angle of 45° on the
target which, during the deposition, is moved by a
computer controlled translation system in order
to avoid overheating and drilling: an area of
about 2 cm2 is scanned, one or more times
depending on the total number of pulses,
during deposition time.
(c)The soluble layer covered by a second layer
containing OLC/UDD-DOX nanoparticles was used
as a substrate for a second MAPLE deposition of
anti-EGFR antibodies. The target was a saline
solution of EGFR or EGR, the guest compound,
frozen by thermal contact with liquid nitrogen.
The MAPLE deposition (deposition parameters are
detailed in Table 1) ensures again that previous
layers were not damaged or removed.
(d)Finally, the microscope cover glass with the
resulting multilayer deposition over soluble substrate
was immersed in a saline solution as solvent. The
soluble substrate dissolved and the nanoparticle
layer disintegrated into individual antibody-OLC/
UDD-DOX units.
Cytotoxicity of CNMs
The cytotoxicity of DOX, UDD-DOX, and OLC-DOX
was evaluated against MCF-7 and HT29 tumor cell
using MTT assay. MTT test based on conversion of 3-
[4,5-dimetltiazol-2]-2,5-dipheniltetratetrazolium salts to
farmasan crystals by NAD(P)H-dependent mitochondrial
oxidoreductase enzymes in alive cells. Protocol was de-
scribed by T. Mosmann [33]. In brief, 1 × 104 MCF-7 or
HT29 were seeded in 96-well plates and cultured in full
culture medium for 12 h. Then, current culture medium
was replaced by culture medium containing DOX,
UDD-DOX, and OLC-DOX. Cells which were cultured
in full medium were used as control. After 24 h of incu-
bation, cells were analyzed with (MTT) by colorimetric
assay. To 100 μl of cells suspension, we added 20 μl
MTT solution (5 mg/ml PBS, Sigma). After that, cells
were incubated with MTT during 4 h in standard condi-
tions. Then, samples were centrifuged under 1500 g,
during 5 min, and supernatant was extracted. In all, wells
were added 10 μl DMSO (Sigma) for MTT crystals
dilution and 20 μl of 25 mM glycine. The absorbance
of reacted solution was measured at 540 nm on spec-
trophotometric plate reader Multyscan (Labsystem,
Finland). The cell viability in the tested concentration
Fig. 3 A scheme of matrix-assisted pulsed laser evaporation techniques shows principal of protein deposition on carbon surface. Antibodies to
human epidermal growth factor receptor and epidermal growth factor were placed on target platen and evaporated on substrate. As substrates
UDD-DOX (samples C46, C47) or OLC-DOX (samples C36, C37), films were used
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range of CNMs was determined by the following
equation:
Cell viability; % ¼ Absorbance of test groupð Þ  100
 Absorbance of control groupð Þ:
Three replicates were used for control and test groups.
Absorbance for each sample was determined three
times.
Sandwich ELISA
The sandwich enzyme-linked immunosorbent assay
(ELISA) measures the amount of antigen between two
layers of antibodies (i.e., capture and detection antibody).
The antigen to be measured must contain at least two
antigenic sites capable of binding to antibody, since at
least two antibodies act in the “sandwich” (Fig. 4). In this
work, protocols which were recommended by producers
of antibodies Sigma®, USA and Calbiochem®, Germany,
were used. As Capture antibody, we used rabbit mono-
clonal anti-epidermal growth factor (EGF) antibody
(SAB 2104809, Sigma, USA). As detection antibody,
mouse polyclonal anti-EGF (clone 2 F1, WH0001950M1,
Sigma, USA) was used. For visualization, as secondary
antibody, goat anti-mouse IgG peroxidase conjugate
(№ 401253, Calbiochem, Merck, Germany) was chosen.
EGF human recombinant, purchased by Sigma, USA (SRP
3027, Sigma, USA), was used as an antigen. As substrate,
we used 3,3,5,5-tetramethylbenzidine (TMB, № 613544,
Calbiochem, Merck, Germany). Detecting antibody in ×10
concentration was object of MAPLE deposition on UDD-
DOX or OLC-DOX films (C37 and C47 samples). For
MAPLE deposition in samples C36 and C46, rabbit
monoclonal anti-EGF-r antibody (clone SP9, RMPD020,
Diagnostic Biosystems, USA) was used. After MAPLE de-
position of the antibodies on the substrate form saline and
water solution of UDD/OLC-DOX particles, the samples
were immersed in saline (1 ml) and resolved by incubation
Table 1 MAPLE deposition parameters
Sample C36 C37 C46 C47
1st MAPLE deposition
Guest OLC-DOX OLC-DOX UDD-DOX UDD-DOX
Matrix Saline solution 7.2 mg
NaCl/1.0 ml H2O
Saline solution 7.2 mg
NaCl/1.0 ml H2O
Water Water
Target 10 mg guest/1.0 ml matrix 10 mg guest/1.0 ml matrix 10 mg guest/1.0 ml matrix 10 mg guest/1.0 ml matrix
Pulse energy 102 mJ/pulse 102 mJ/pulse 191 mJ/pulse 123 mJ/pulse
Number of pulses 4400 pulses 4400 pulses 8800 pulses 8800 pulses
Target to substrate 18 mm 10 mm 18 mm 10 mm
2nd MAPLE deposition
Guest Monoclonal rabbit anti-EGFR
(clone SP9, RMPD 020,
Diagnostic BioSystems, USA)
Monoclonal mouse anti-EGF
(clone 2 F1, WH0001950M1,
Sigma, USA)
Monoclonal rabbit anti-EGFR
(clone SP9, RMPD 020,
Diagnostic BioSystems, USA)
Monoclonal mouse anti-EGF
(clone 2 F1, WH0001950M1,
Sigma, USA)
Matrix Saline solution 9.0 mg
NaCl/1.0 ml H2O
Saline solution 9.0 mg
NaCl/1.0 ml H2O
Saline solution 9.0 mg
NaCl/1.0 ml H2O
Saline solution 9.0 mg
NaCl/1.0 ml H2O
Target 2.0 ml guest/8.0 ml matrix 2.0 ml guest/8.0 ml matrix 2.0 ml guest/8.0 ml matrix 2.0 ml guest/8.0 ml matrix
Pulse energy 263 mJ/pulse 191 mJ/pulse 360 mJ/pulse 191 mJ/pulse
Number of pulses 8800 pulses 4400 pulses 8800 pulses 4400 pulses
Target to substrate 18 mm 10 mm 18 mm 10 mm
Both MAPLE depositions
Target scanned area 1.7 cm2 1.7 cm2 1.7 cm2 1.7 cm2
Laser type Q-switched Q-switched Q-switched Q-switched
Nd:YAG Nd:YAG Nd:YAG Nd:YAG
Laser wavelength 1064 nm 1064 nm 1064 nm 1064 nm
Pulse duration 10 ns 10 ns 10 ns 10 ns
Pulse repetition rate 4 pulses/s 4 pulses/s 4 pulses/s 4 pulses/s
Spot size (elliptical) 1.0 mm × 1.4 mm 1.0 mm × 1.4 mm 1.0 mm× 1.4 mm 1.0 mm× 1.4 mm
Target temperature 145 K 145 K 145 K 145 K
Chamber pressure 10−4 Pa 10−4 Pa 10−4 Pa 10−4 Pa
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on a rotary shaker (80 rpm) for 24 h at room temperature.
Then, the activity of antibody were tested by ELISA pro-
cedure as a reaction immunoassay as detecting antibody.
Statistical Analysis
Section of statistics, dedicated to processing of small
samples (2 ≤ n <20), conventionally called micro-
statistical. Underlying micro-statistical estimates of
normally distributed random variables is the Student’s
distribution for small quantities. Reported p values was
*p < 0.05 or **p < 0.01.
Results and Discussion
FT-IR Spectroscopy of UDD-DOX Particles
Figure 5 shows FT-IR spectra of UDD, DOX, and UDD-
DOX particles. The main features of UDD (Fig. 5a) cor-
respond to existing quite intense peaks of carbohydrate
linkages in the region of 1717 cm−1. It indicates the
presence of carboxyl groups. There was also a shift and
decrease in intensity of the C–O covalent band vibra-
tions, which were fixed at 1619–1589 cm−1. Also, in
samples, low vibration peaks of aromatic C–H groups
(792 cm−1) were demonstrated. Meanwhile, some car-
bonyl groups can emerge from adsorbed CO and CO2
(at 1102 and 1247 cm−1, respectively) in UDD spectra.
The appearance of a vibration at 1359 cm−1 is evidence
of the presence in UDD of cyclic carbon groups. Figure 5
demonstrates FT-IR spectra of DOX (b) and UDD-DOX
particles (c). It shows characteristic picks from UDD and
DOX even after several cycles of washing and centrifu-
gation of nanomaterials.
In Vitro DOX Release from CNMs-DOX Particles by
Trypsinization
The treatment of the oxidized carbon nanomaterial
(UDDox, OLCox) solutions in water soluble carbodii-
mide hydrochloride and DOX led to formation of cova-
lent peptide bonds between DOX and carbon surface.
Such bonds are strong at phosphate-buffered saline
(PBS, pH 7.7) at temperatures ranged of 35.0–37.0 °C.
Therefore, controlled release of DOX was the task of the
next step of our work. For decomposition of UDD-DOX
and OLC-DOX conjugates and DOX release, we used
trypsin. Trypsin is one of the best characterized serine
proteases [34]. The concentration of trypsin in our study
was 0.25 mg/ml (0.25 w/v) in serum-free DMEM. The
trypsin as pancreatic enzyme is involved in hydrolysis of
peptide bonds by sites of carboxyl groups of serine
amino acids. The UDD-DOX and OLC-DOX particles in
a concentration of 650 μg/ml were incubated with tryp-
sin at concentrations from 0.2 to 5.0 μg/ml at 37.0 °C in
dark during 24 h. The concentration of attached DOX
was 20 μg/ml. After incubation, the 96-well plates were
centrifuged. Supernatant from wells was filtered through
a filter with a pore size of 0.22 μm. The absorbance of
supernatant was measured using a spectrophotometric
plate reader at the wavelength 490 nm. The amount of
free DOX was calculated according to the calibration
line. As a result, it was found dose-dependent increasing
of the concentration of free DOX after incubation with
trypsin (Fig. 6). Interestingly, that correlation between
concentration of trypsin and free DOX is positive but
is not proportional. DOX release has stepped-like
Fig. 4 Scheme of sandwich ELISA method
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tendency. For example, for the UDD-DOX complex,
at trypsin concentrations of 0.2–0.3 μg/ml, the concentra-
tion of the released DOX was about 3.22 μg/ml; at trypsin
concentrations 0.6–3.75 μg/ml, concentration of the
released was equal 6.5–6.8 μg/ml; and at trypsin concen-
tration 5.0 μg/ml, free DOX concentration has risen to
11.31 μg/ml. For complex OLC-DOX, also, observed step-
wise trends of growth the concentration of free DOX. At
trypsin concentrations from 0.2 to 0.6 μg/ml and 1.3 to
2.5 μg/ml, changing in concentration of DOX was
statistically insignificant (6.0–6.6 and 7.6–7.7 μg/ml, re-
spectively). In the case of trypsin concentration 5.0 μg/ml,
the concentration of the free DOX has reached 12.18 μg/
ml. Thus, it can be assumed that trypsin can destroy the
covalent peptide bonds between DOX and the carbon sur-
face and facilitate controlled release of the active sub-
stance. More than that, the efficiency of such peptidase
action as destruction of covalent peptide bonds and the
amount of released DOX depends on specificity of the
three-dimensional structure of the carbon substrate.
Fig. 6 Cleavage of UDD-DOX and OLC-DOX conjugates and release of free doxorubicin upon incubation with trypsin at 37.0 °C in dark during
24 h. Each experiment was carried out in triplicates. Concentration of free doxorubicin was calculated by spectrophotometer absorbance and
calibration lines at 495 nm
Fig. 5 FT-IR spectra of UDD (a), DOX (b), and UDD-DOX (c)
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Placement of Nanomaterials, DOX, and Antibodies on
Cover Slips
Another problem which considerably limits the usage of
anticancer drugs is non-specific toxicity. Chemotherapy
is associated with significant drug leakage into systemic
circulation and non-specific distribution to healthy tis-
sue. In results, chemotherapy correlates with severe car-
diac, neuronal, hepatic, kidney, and bone narrow toxicity
[35, 36]. Therefore, the task of targeted delivery of anti-
cancer drugs still remains actual, and it is not solved yet.
Application of tissue-specific antibody is seemed as one
of the possible ways to resolve this task. Tumor cells of
breast cancer (MCF-7 cell line) are characterized of high
secretion of EGF and over expression of EGF receptors.
EGFR is widely used as a marker in diagnostic of malig-
nant growth. That is why, EGFR is a promising target
for specific delivery of chemotherapeutic agents. With
this mind, the task was to find a method of placement of
complex protein molecules on carbon surface and at the
same time not to destroy it tertiary structure and func-
tional activity. Therefore, MAPLE technology was used
for deposition of antibodies to EGFR on UDD-DOX or
OLC-DOX surface (Fig. 7).
Verification of Antibody to EGF Activity by ELISA
In order to determine the activity of antibodies after
MAPLE deposition procedure on the surface of the
carbon, we used two types of antibodies: C36 and
C46—antibody to human EGFR from rabbit and C37
and C47—antibody to human EGF from mouse
(Table 2). Activity of all samples analyzed by sand-
wich ELISA.
Samples C36 and C46 were used as a negative control,
since they did not participate in ELISA reaction. Mouse
antibodies to EGF which did not pass through MAPLE
placement process were used as control sample. Human
EGF was used as active substrate in ELISA assay. In re-
sults, binding activity of anti-EGF antibodies decreased
slightly after placement in samples C37 and C47. Activ-
ity of antibody decreased by 18–22 % in C36 samples
compared with the control. In C46 samples, activity of
antibody decreased by 11–12 % (Fig. 8). At the same
time, negative control non-specific binding in C36 and
C46 samples provided 3 % of experimental error. It is
possible that non-specific binding appears due to bovine
serum albumin in ELISA protocol and illustrates the de-
gree of reliability of the experimental deviations from
the control samples. Nevertheless, the resulting antibody
activity in C37 and C47 samples is quite high, about
75 % after MAPLE deposition. Samples C36 and C46
will be used for follow-up test of activity of antibodies
after MAPLE placement in immunohistochemistry stain-
ing in further experiments. Authors are aware that only
after a comprehensive analysis by different methods, we
can make a conclusion about effectiveness of proposed
method for placing the antibodies on the surface of the
carbon films.
Cytotoxicity of Carbon-DOX Conjugates after Incubation
It with Trypsin
Cytotoxicity of DOX after releasing from the NCPCs
was evaluated in vitro on monolayer cell cultures of
hepatocellular carcinoma (HT29) and breast adenocar-
cinoma (MCF-7). For test, nine groups were formed
Fig. 7 A schematic drawing shows structure of EGF-antibody-UDD-DOX conjugates. Microphotography of carbon-protein films after MAPLE
deposition. Images were acquired using Zeiss Flouval ×40 water immersion lens. a C36 sample, saline solution of UDD-DOX-rabbit antihuman
EGFRa/b. b C37 sample, saline solution OLC-DOX-mouse antihuman EGFa/b
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(Table 3). 1 × 104/well tumor cells (MCF-7 or HT29)
were seeded in a 96-well plate. The cells were incubated
in full medium during 24 h. After that, medium was
changed for serum-free and trypsin. Then, UDD-DOX
or OLC-DOX was added to cell culture. After 24 h of
cultivation at standard condition cells, viability was mea-
sured by MTT assay. For estimation of possible cytotoxic
influence of pure trypsin in experiments, trypsin control
groups were added. Concentrations of trypsin in serum-
free DMEM were demonstrated in Table 3. Figure 9 shows
that even high concentrations of trypsin (125,250 μg/ml)
did not lead to statistically significant effect on tumor cell
viability. It is possible, because period of cultivation was
rather brief. Another explanation to this fact is in in-
creased resistance of tumor cells both to lack of nutrients
(FBS) and to cytotoxic agents (trypsin). At the same time,
it was found that increasing the concentration of trypsin
and NCPCs correlated with decreasing of tumor cell sur-
vival. In group 1 at minimum concentration of trypsin
(31.25 μg/ml) and NCPCs (84–2.5 μg/ml), level of tumor
cell viability was the highest (from 90 to 66 %, depends on
group). On the other hand, the increasing concentration
of NCPCs and trypsin led to decreasing of tumor cell via-
bility in both cell lines. It is worth to note that sensitivity
of tumor cells depended on concentration of active ingre-
dients and type of carbon in conjugates. Overall UDD-
DOX conjugates were more cytotoxic than OLC-DOX. In
addition, breast adenocarcinoma cells, MCF-7, were more
sensitive to the action of the NCPCs-DOX (as to UDD-
DOX as to OLC-DOX) than HT29 cells. For example,
survival of adenocarcinoma cells was reduced from 52 to
28 % in case of incubation with the UDD-DOX (Fig. 9,
groups 1–4, UDD-DOX MCF-7) and from 72 to 30 % in
case of incubation with OLC-DOX (Fig. 9, groups 1–4,
OLC-DOX MCF-7). Hepatocellular carcinoma cells
(HT29) appeared to be less sensitive to DOX. Increasing
concentrations of trypsin and NCPCs-DOX correlated
with decreasing of cell viability from 69 to 56 % in case of
incubation with the UDD-DOX (Fig. 9, groups 1–4, UDD-
DOX, HT29) and from 91 to 75 % in case of incubation
with OLC-DOX (Fig. 9, groups 1–4, OLC-DOX, HT29).
One of the main goals of this experiment was to test
methods of synthesis of antitumor nanocarbon-protein
conjugates with specific antibodies to the tumor recep-
tors epidermal growth factors and metabolic drug. An-
other aim was to approbate methodology of controlled
releasing of DOX in tumor cell culture. Unique physical
and chemical properties of carbon nanomaterials are
complemented by extremely interesting biological prop-
erties. Onion-like carbons (OLCs) and ultra dispersed
diamonds (UDDs) have great potential for application in
biology, medicine, and biotechnology [37–39]. There
were many efforts to employ carbon nanomaterials as
tool for anticancer therapy [25, 40–45]. But there are a
lot of unclear aspects of CNM interaction with tumor
cells. Toxicity and carcinogenicity has been one of the
major concerns for OLCs and UDDs use in biomedical
application [46, 47]. Our previous studies showed low
Table 2 Description of antibody in samples for MAPLE deposition
Sample C36 C37 C46 C47
2nd MAPLE
deposition
Application: immunohistochemistry Application: ELISA Application: immunohistochemistry Application: ELISA
Guest Monoclonal rabbit anti-EGFR Monoclonal mouse anti-EGF Monoclonal rabbit anti-EGFR Monoclonal mouse anti-EGF
Fig. 8 Activity of anti-EGF antibodies after MAPLE deposition in sandwich enzyme-linked immunosorbent assay
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cytotoxicity and good biocompatibility of UDDs and
OLCs [26]. At the same time, we have found that the
UDDs and OLCs can act as centers for cell cohesion and
migrating in suspension. In this case CNMs can stimu-
late metastasis formation. Nevertheless, we suggested
that UDDs and OLCs may be successfully functionalized
by drug, such as DOX. Practically effective ammoniza-
tion of carbon surface and high-sorption activity pro-
vided rather good functionalization of UDDox and
OLCox by DOX. In addition, data from Hua et al. [48]
and Kopecek et al. [49] demonstrated that drugs could
be successfully released from carbon compounds. And,
effectiveness of this process depends on the type of
established connection. It was suggested that proteolysis
enzymes such as trypsin will destroy covalent protein
bonds in NCPCs. The concentration-dependent DOX
release from UDD/OLC-DOX particle was realized by
trypsin peptide bond decomposition. Correlation be-
tween concentration of trypsin and the amount of free
DOX was typical for enzymatic reaction with substrate
[50, 51]. It is indicated that release of DOX from NCPCs
with UDDs and OLCs have enzymatic dose-dependent
mechanism. This fact let us concluded that such prote-
olysis enzymes as pepsin, chemotropism, enterokinase,
and elastase may be perspective for further decompos-
ition of covalent peptide bonds in nanovehicles. The
presence of these enzymes in gastric and intestinal se-
crets in normal and over secretion in cancer tissue [34]
could provide natural cleavage of drugs from the carbon
substrate in the stomach and intestines [36]. This
process will provide targeted penetration of the drug
into the zone of formation of colon or stomach cancer.
Problem of targeted release of drugs can be resolved in
another way. For examples, there are some studies of
coating of nanodiamonds with PEG, silica, and polyme-
tacrylate copolymers. The polymers enable to saturate
the matrix by biologically active growth factors and cyto-
kines with followed enzyme-dependent release in tissues
[52]. Another functionalization of polymeric materials
was demonstrated by Ehrbar with colleagues [53]. This
work focused on tissue repair and not to its destruction,
as is the case with the tumor. Nevertheless, the modifi-
cation of nanostructured materials by their encapsula-
tion in polymeric materials and further saturation with
Table 3 Composition of culture medium in experimental groups
DMEM, μl PBS, μl
Control 0 100 0
Control group 1 50 62.5
Control group 2 50 75.0
Control group 3 50 130
Control group 4 50 220
DMEM, μl CNMs-DOX, μg/ml Trypsin, μg/ml
Trypsin control group 1 100 0 31.25
Trypsin control group 2 100 0 62.5
Trypsin control group 3 100 0 125
Trypsin control group 4 100 0 250
Group 1 50 84–2.5 31.25
Group 2 50 167–5 62.5
Group 3 50 335–10 125
Group 4 50 670–20 250
Fig. 9 The survival of tumor MCF-7 and HT29 cells in concentration of 1 × 104 cell/ml after incubation with the carbon-protein complexes UDD-DOX
and OLC-DOX in the presence of trypsin. Cells were incubated in full medium 24 h and in presence of trypsin in serum-free medium next 24 h.
Cell survival was evaluated by MTT assay
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antitumor drugs and specific antibodies seems to us
promising area of research [54]. Such constructions
allow to modulate the drug release conditions according
to the target tissue and the activity of its enzyme and
tumor marker. Another significant problem of targeted
delivery of drugs is the placement on the surface of the
carbon particle-specific antibodies. Tumor cells have a
specific receptor profile. These properties are the base
for the diagnosis, prognosis of the disease, and develop-
ment of treatment regimens for cancer patients. Thus,
the “anti-receptor” drugs rather expensive and require
the use of high doses. DOX as well as other antimetabo-
lites and cytotoxic drugs have a wide range of harmful
side effects on the body. Both referred approaches have
advantages and disadvantages that limited the thera-
peutic application of drugs. For effective combination of
cytotoxic and receptor-attractive approach, we use
MAPLE technology of protein deposition. Early was re-
ported that laser evaporation technique let safe activity
of protein on rather high level [55, 56]. There are a lot
of works with goals to attach specific antibodies to
matrix [57, 58]. The main challenge in this work was to
safe biological activity of antibody to EGF. Our results
for the antibody activity are quite optimistic. Activity of
anti-EGF antibodies was on the level 75 % after MAPLE
deposition and in PBS. For testing antibody activities,
ELISA method was used. Our results may be also veri-
fied by immune histochemistry methods with samples
C37 and C47 and fluorescence microscopy. In fact, the
inclusion of IHC and microscopy with high resolution
would enable to confirm once more effectiveness of
MAPLE technology for protein. In addition, fluorescence
microscopy allows to observe distribution of NCPCs and
its particles in cells. Another limitation of our work is
that our research focuses only on cytological influence
and characteristics of NCPCs, whereas it might be im-
portant to include more chemical characteristics of
NCPCs. It is in our future plans.
Conclusions
Synthesis of carbon protein construct on the basis of
ultra dispersed diamond, onion-like carbon, anticancer
drug (DOX), and anti-EGFR antibodies demonstrated
fruitful cooperation of chemistry and biology. A new
DOX delivery vehicle has been developed by step-by-
step synthesis, cleaning, oxidation, functionalization with
oxygen containing acidic groups (carboxylic—COOH,
hydroxyl—OH), and immobilization of DOX on carbon
surface of UDDox and OLCox. The effectiveness of
functionalization was 2.94 % w/w for OLC-DOX and
2.98 % w/w for UDD-DOX. Here, dose-dependent,
stepped-like increasing concentration of free DOX after
incubation UDD-DOX and OLC-DOX conjugates with
trypsin was described. It is demonstrated the effectiveness
of trypsin as DOX release agent and UDD/OLC-DOX
particles as drug delivery nanosystem. In addition in this
paper, it has been shown that trypsin-mediated release of
DOX has dose-dependent negative correlation with tumor
cell viability. The survival of adenocarcinoma cells (MCF-
7) reduced from 52 to 28 % in the case of incubation
during 24 h with the UDD-DOX in concentrations from
8.4–2.5 μg/ml to 670–20 μg/ml and from 72 to 30 % after
incubation with OLC-DOX at the same time and same
concentrations. Sensitivity of hepatocellular carcinoma
cells (HT29) to DOX was higher than MCF-7. This data
illustrated that looking for appropriate drugs and system
of delivery may be very complicated process even for cells
of same epithelial genesis. For this purpose, possibility of
deposition of specific anti-EGF antibodies of carbon sur-
face by MAPLE technology was tested. Biological activity
of anti-EGF antibodies after MAPLE deposition and PBS
was near 75 %, which depended on technology of depos-
ition and type of carbon film. Thus, on the basis of these
results, we assume that NCPCs on the bases of UDDs and
OLCs loaded with drugs and specific antibodies may be
useful for effective antitumor agent delivery.
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